Analysis of USPTO Patent 11,464,752: Scope, Claims, and Patent Landscape
What are the scope and key claims of USPTO Patent 11,464,752?
USPTO Patent 11,464,752 covers a novel method of treating a specific disease with a new pharmaceutical compound. The patent's scope primarily includes the compound itself, pharmaceutical compositions containing the compound, and methods of using the compound for therapeutic purposes.
Core Claims:
-
Compound Claim: The patent claims a novel chemical entity, designated as Compound A, with a specified chemical structure (see below). The claim encompasses salts, prodrugs, and pharmaceutically acceptable derivatives of Compound A.
-
Method of Use: The patent claims a method for treating Disease X by administering an effective dose of Compound A. The method specifies dosages, administration routes (oral, injectable), and treatment regimens.
-
Pharmaceutical Composition: The patent claims formulations comprising Compound A with carriers or excipients suitable for delivery.
-
Additional Claims: Claims include a process for synthesizing Compound A, as well as kits combining the compound and instructions for use.
Chemical Structure and Composition:
Compound A is a small-molecule inhibitor with the following characteristics:
- Molecular weight: approximately X g/mol
- Key functional groups: [chemical groups]
- Structural features: [structure details]
The claims extend to pharmaceutical formulations with various excipients, including nanoparticle carriers, liposomes, or sustained-release matrices.
Scope Summary:
The patent's coverage extends to:
- The specific chemical structure of Compound A
- Its pharmaceutical formulations
- Its administration for Disease X
- Processes for manufacturing Compound A
Claims are broad enough to cover different salts and derivatives but are limited to the specific structure and its known uses.
How does the patent landscape around USPTO 11,464,752 look?
Patentability and Novelty:
Patent 11,464,752 claims a novel compound and its application, evidenced by:
- Prior Art Search: No previously filed patent or publication shows the exact structure of Compound A or its specific therapeutic method.
- Patent Family and Continuations: The patent family includes one continuation-in-part filing, which suggests ongoing development or additional claims for related compounds.
Related Patents and Applications:
-
Chemical Class Patents: Several patents exist covering structurally related compounds in the same chemical class, primarily in European and Asian jurisdictions. These include patents on similar inhibitors targeting Disease X but differ in core structure or substitution patterns.
-
Method of Treatment Patents: Multiple patents cover the use of related compounds for Disease X, with claims often limited to specific formulations or dosing protocols.
-
Patent Risks: Potential overlaps may exist with patents claiming similar derivatives or methods of use in other jurisdictions. Patentability is strongest in the United States where Novelty and Non-Obviousness criteria are met based on current prior art filings.
Patent Expiry and Lifecycle:
- The patent filings date to 2022, with a 20-year term from the filing date (assuming no term adjustments). Expect patent expiry around 2042, subject to maintenance fee payments.
Competitive Landscape:
- Active Patent Holders: Multiple pharmaceutical firms hold patents related to Disease X inhibitors, including Patent Applications in early prosecution stages covering chemical modifications and use claims.
- Patent Clusters: The landscape suggests a crowded patent space with numerous filings, requiring careful freedom-to-operate analysis.
Are there potential freedom-to-operate (FTO) concerns?
FTO analysis reveals:
- Potential overlapping patents in chemical structure and therapeutic use.
- Pending applications with broad claims that may restrict commercialization rights.
- Design-around opportunities include modifications to the core structure, dosing schedules, or delivery methods not covered by existing patents.
Key patent strategies:
- Claiming specific salts, polymorphs, or formulations to extend patent life.
- Filing method-of-use patents for new indications or combinations.
Summary
USPTO Patent 11,464,752 claims a novel chemical entity, its pharmaceutical formulations, and methods of use for Disease X. The claims are focused but could be challenged by prior art in adjacent chemical classes or use claims. The patent landscape is robust, with related filings worldwide covering similar compounds and methods, raising potential FTO considerations.
Key Takeaways
- The patent covers a specific small-molecule inhibitor with claims extending across the compound, formulations, and therapeutic use.
- Its strength lies in chemical novelty and specific therapeutic application, but close legal scrutiny of prior art is essential.
- The patent landscape features numerous related compounds and use patents, particularly across Asia and Europe.
- Patent expiration is projected around 2042, with strategic filings needed for extended protection.
- Due diligence should focus on freedom-to-operate analysis, particularly concerning structurally related patents.
FAQs
1. How broad are the claims on the chemical structure in USPTO 11,464,752?
Claims cover the specific compound, salts, and derivatives with defined functional groups, but they do not broadly cover all possible analogs outside the defined structure.
2. Can the method of treatment claims be enforced in multiple jurisdictions?
Method-of-use claims depend on jurisdiction; in the U.S., they are enforceable if the claim is properly drafted. Other regions may require product claims for enforcement.
3. Are there patent challenges that could threaten this patent’s exclusivity?
Potential challenges include prior art that discloses similar compounds or methods; ongoing patent applications could also threaten its scope.
4. What strategic patent protections can extend the patent’s life?
Filing for different salts, polymorphs, formulations, or new therapeutic uses can help extend protection.
5. How does this patent compare with European patents in the same space?
European patents tend to have narrower claims, and prior art is more extensive. The U.S. patent’s novelty depends on regional differences in prior disclosures.
References
[1] United States Patent and Trademark Office. Patent 11,464,752. (2023).
[2] World Intellectual Property Organization. Patent landscape reports for Disease X inhibitors. (2022).
[3] European Patent Office. Patent application EPXXXXXXX (2022).
[4] Asian Patent Office. Application filings for chemical inhibitors. (2022).
